tradingkey.logo

Stifel initiates Palvella with 'buy' rating on skin treatment prospects

ReutersMar 26, 2025 2:53 PM

Brokerage Stifel starts coverage on drug developer Palvella Therapeutics PVLA.O with "buy" rating and $45 PT

New PT represents a 65% upside to the stock's last close

Stifel thinks PVLA has the potential to build a portfolio of rare skin disease treatments, "which collectively could have multi-billion-dollar potential"

Stifel notes co's gel QTORIN optimizes for delivery of the treatment into the deepest regions of the skin with potency and high patient tolerability

Including session's moves, PVLA stock more than doubled YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI